MicroPort Scientific Corp. logo

MicroPort Scientific Corp.

0853.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$6.28

−HK$0.31 · -4.70%

Aug 24, 11:59 AM HKT

0853.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Jonathan W. Chen
Listed since
Sep 24, 2010
Employees
6,547

Market position

Day range

Current HK$6.28

52-week range

Current HK$6.28

Open
HK$6.505
Previous close
HK$6.59
Volume
8.34M
0.67× average
Average volume
12.47M
Average daily volume
Market cap
12.01B HKD
Beta
0.36
Market reference 1
50-day average
HK$6.6843
-6.05% below average
200-day average
HK$9.2479
-32.09% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.52B USD
P/E (TTM)
32.31×
P/B (TTM)
1.35×
P/S (TTM)
1.54×
EV / EBITDA
39.63×
Earnings yield
1.87%
Free cash flow yield
-2.99%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
55.18%
Operating margin
-3.73%
Net margin
4.89%
Return on equity
4.95%
Return on assets
1.31%
Return on invested capital
-1.65%

Financial health

Debt / equity
1.63×
Current ratio
1.45×
Altman Z-score
0.41
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends75%26%-23%-73%Gross margin, FY2021: 63.16%Gross margin, FY2022: 59.68%Gross margin, FY2023: 55.97%Gross margin, FY2024: 55.68%Gross margin, FY2025: 55.63%Operating margin, FY2021: -37.71%Operating margin, FY2022: -60.25%Operating margin, FY2023: -54.29%Operating margin, FY2024: -12.47%Operating margin, FY2025: -5.31%Net margin, FY2021: -35.51%Net margin, FY2022: -51.91%Net margin, FY2023: -50.24%Net margin, FY2024: -20.76%Net margin, FY2025: 4.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.16%. Gross margin FY2022 59.68%. Gross margin FY2023 55.97%. Gross margin FY2024 55.68%. Gross margin FY2025 55.63%. Operating margin FY2021 -37.71%. Operating margin FY2022 -60.25%. Operating margin FY2023 -54.29%. Operating margin FY2024 -12.47%. Operating margin FY2025 -5.31%. Net margin FY2021 -35.51%. Net margin FY2022 -51.91%. Net margin FY2023 -50.24%. Net margin FY2024 -20.76%. Net margin FY2025 4.88%.

Income trends

Revenue

996.38M USD-3.36%

Operating income

−52.95M USD+58.82%

Net income

48.59M USD+262.63M USD
Income trends across reported periods1.19B USD566.89M USD−52M USD−670.89M USDRevenue, FY2021: 778.64M USDRevenue, FY2022: 840.83M USDRevenue, FY2023: 950.73M USDRevenue, FY2024: 1.03B USDRevenue, FY2025: 996.38M USDOperating income, FY2021: −293.62M USDOperating income, FY2022: −506.57M USDOperating income, FY2023: −516.17M USDOperating income, FY2024: −128.58M USDOperating income, FY2025: −52.95M USDNet income, FY2021: −276.48M USDNet income, FY2022: −436.52M USDNet income, FY2023: −477.63M USDNet income, FY2024: −214.04M USDNet income, FY2025: 48.59M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 778.64M USD. Revenue FY2022 840.83M USD. Revenue FY2023 950.73M USD. Revenue FY2024 1.03B USD. Revenue FY2025 996.38M USD. Operating income FY2021 −293.62M USD. Operating income FY2022 −506.57M USD. Operating income FY2023 −516.17M USD. Operating income FY2024 −128.58M USD. Operating income FY2025 −52.95M USD. Net income FY2021 −276.48M USD. Net income FY2022 −436.52M USD. Net income FY2023 −477.63M USD. Net income FY2024 −214.04M USD. Net income FY2025 48.59M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue996.38M USD1.03B USD950.73M USD840.83M USD778.64M USD
Cost of goods sold442.05M USD456.97M USD418.63M USD339.06M USD286.87M USD
Gross profit554.33M USD574.09M USD532.1M USD501.77M USD491.77M USD
Research and development135.7M USD216.52M USD379.43M USD431.02M USD297.78M USD
Selling, general, and administrative465.65M USD484.68M USD540.73M USD575.76M USD560.49M USD
Operating expenses608.1M USD702.67M USD1.05B USD1.01B USD831.02M USD
Interest income14.6M USD22.75M USD29.4M USD19.11M USD15.83M USD
Interest expense111.43M USD102.24M USD92.73M USD73.91M USD42.71M USD
Depreciation and amortization141.78M USD93.43M USD151.25M USD76.31M USD57.46M USD
Operating income−52.95M USD−128.58M USD−516.17M USD−506.57M USD−293.62M USD
Net income48.59M USD−214.04M USD−477.63M USD−436.52M USD−276.48M USD

Company facts updated Aug 24, 2026.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.043

2021 complete year+126.3% since 2017

Corporate action history

Dividend

Ex-dividend Jun 28, 2021

HK$0.043

Annual

Record Jun 29, 2021 · Payment Aug 18, 2021

Dividend

Ex-dividend Jun 22, 2020

HK$0.053

Annual

Record Jun 23, 2020 · Payment Aug 17, 2020

Dividend

Ex-dividend Jun 17, 2019

HK$0.029

Annual

Record Jun 18, 2019 · Payment Aug 15, 2019

Dividend

Ex-dividend May 16, 2018

HK$0.025

Annual

Record May 17, 2018 · Payment Aug 15, 2018

Dividend

Ex-dividend Jun 22, 2017

HK$0.019

Annual

Record Jun 23, 2017 · Payment Aug 15, 2017

Dividend

Ex-dividend Jun 28, 2013

HK$0.08

Annual

0853.HK peers

ETFs holding 0853.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 0853.HK

research.disclaimer